Infant Bacterial Therapeutics AB is a clinical stage pharmaceutical company, which engages in the development of drugs for the treatment of rare diseases affecting premature infants. Its products include IBP-9414 and IBP-1016. The IBP-9414, is a drug candidate contains Lactobacillus reuteri which is a human bacterial strain naturally present in breast milk that improves feeding tolerance in premature infants and IBP-1016, helps in treating gastroschisis, a severe birth defect in infants. The company was founded in 2013 and is headquartered in Stockholm, Sweden.
Sector:
Health Technology
Industry:
Pharmaceuticals Major
Employees:
8
Frequently Asked Questions
What is Market Cap of Infant Bacterial Therapeutics AB - Ordinary Shares - Class B?
Market cap, also known as market capitalization, is the total market value of a company. It’s calculated by multiplying the current market price by the total number of shares outstanding. Infant Bacterial Therapeutics AB - Ordinary Shares - Class B market cap is $867.56M.
What is the 52-week high for Infant Bacterial Therapeutics AB - Ordinary Shares - Class B?
52 week high is the highest price of a stock in the past 52 weeks, or one year. Infant Bacterial Therapeutics AB - Ordinary Shares - Class B 52 week high is $8.20 as of October 17, 2025.
What is the 52-week low for Infant Bacterial Therapeutics AB - Ordinary Shares - Class B?
52 week low is the lowest price of a stock in the past 52 weeks, or one year. Infant Bacterial Therapeutics AB - Ordinary Shares - Class B 52 week low is $8.20 as of October 17, 2025.
What is Infant Bacterial Therapeutics AB - Ordinary Shares - Class B stock price today?
Infant Bacterial Therapeutics AB - Ordinary Shares - Class B stock price today is $8.20.
What was Infant Bacterial Therapeutics AB - Ordinary Shares - Class B stock price yesterday?
Infant Bacterial Therapeutics AB - Ordinary Shares - Class B stock price yesterday was $8.20.
What is the PE ratio of Infant Bacterial Therapeutics AB - Ordinary Shares - Class B?
The Price-to-Earnings (or P/E) ratio is a commonly used tool for valuing a company. It’s calculated by dividing the current share price by the earnings per share (or EPS). It can also be calculated by dividing the company’s Market Cap by the Net Profit. Infant Bacterial Therapeutics AB - Ordinary Shares - Class B’s P/E ratio is -11.25.
What is the Price-to-Book ratio of Infant Bacterial Therapeutics AB - Ordinary Shares - Class B?
The Price-to-Book (P/B) ratio is a commonly used tool for valuing a company. It’s calculated by dividing a company’s market capitalization by its book value. Infant Bacterial Therapeutics AB - Ordinary Shares - Class B P/B ratio is 7.8361.
What is the 50-day moving average of Infant Bacterial Therapeutics AB - Ordinary Shares - Class B?
The 50-day moving average is a frequently used data point by active investors and traders to understand the trend of a stock. It’s calculated by averaging the closing stock price over the previous 50 trading days. Infant Bacterial Therapeutics AB - Ordinary Shares - Class B 50-day moving average is $8.20.
How many employess does Infant Bacterial Therapeutics AB - Ordinary Shares - Class B has?
Infant Bacterial Therapeutics AB - Ordinary Shares - Class B has 8 employees.
